Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combinedwith Olfactory Training to Treat Post-COVID-19 OlfactoryImpairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial
Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combinedwith Olfactory Training to Treat Post-COVID-19 OlfactoryImpairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial is a paper indexed in PICO Portal from OpenAlex.
How many citations does Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combinedwith Olfactory Training to Treat Post-COVID-19 OlfactoryImpairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial have?
Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combinedwith Olfactory Training to Treat Post-COVID-19 OlfactoryImpairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial has 109 citations in the OpenAlex counts PICO Portal stores.
When was Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combinedwith Olfactory Training to Treat Post-COVID-19 OlfactoryImpairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial published?
Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combinedwith Olfactory Training to Treat Post-COVID-19 OlfactoryImpairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial has 2022 year in the PICO Portal index.
What is the open-access status of Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combinedwith Olfactory Training to Treat Post-COVID-19 OlfactoryImpairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial?
Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combinedwith Olfactory Training to Treat Post-COVID-19 OlfactoryImpairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial has bronze oa status in the PICO Portal index.
What is the DOI of Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combinedwith Olfactory Training to Treat Post-COVID-19 OlfactoryImpairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial?
The DOI for Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combinedwith Olfactory Training to Treat Post-COVID-19 OlfactoryImpairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial is on the source record.
What is the PMID of Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combinedwith Olfactory Training to Treat Post-COVID-19 OlfactoryImpairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial?
The PMID for Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combinedwith Olfactory Training to Treat Post-COVID-19 OlfactoryImpairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial is on the source record.
What is the OpenAlex record for Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combinedwith Olfactory Training to Treat Post-COVID-19 OlfactoryImpairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial?
The OpenAlex for Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combinedwith Olfactory Training to Treat Post-COVID-19 OlfactoryImpairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial is on the source record.